<DOC>
	<DOCNO>NCT00056758</DOCNO>
	<brief_summary>This study evaluate safety immune response dendritic cell vaccination HIV-1 infection . The vaccine make patient 's cell combine small fragment HIV-1 ( make synthetically laboratory ) . These cell administer back patient either vein ( intravenously ) skin ( subcutaneously ) .</brief_summary>
	<brief_title>HIV Vaccine Designed HIV Infected Adults Taking Anti-HIV Drugs</brief_title>
	<detailed_description>Untreated HIV-1 infection characterize progressive immune dysfunction development opportunistic infection AIDS-associated malignancy . Highly active antiretroviral therapy ( HAART ) successful suppress HIV replication restore partial immune function . However , HIV-specific immunity remain poor , evidence rapid rebound HIV-1 RNA follow HAART withdrawal . Studies individual acute HIV-1 infection , well long-term nonprogressors , suggest robust HIV-specific immune response associate control HIV-1 viremia . Dendritic cell ( DCs ) potent antigen present cell may increase HIV-specific immune response . This protocol evaluate use DCs help control HIV infection . Patients randomize receive either intravenous subcutaneous administration HIV antigen express DCs . Each subject receive two administration mature DCs give 3 week apart . Subjects follow weekly 8 week , Weeks 12 , 16 , 24 , 36 , 48 . Two dos DCs evaluate ( low dose : 1-3 million cell ; high dose : 5-10 million cell ) safety immune system response .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria HIV1 infection Current CD4 count 400/mm3 HIV RNA le 400 copies/ml Stable combination antiretroviral therapy least 4 week prior study entry HLA A2.1 ( test screening ) Exclusion criterion Prior HIV vaccine Systemic steroid immunosuppressive drug within 30 day study entry Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HAART</keyword>
	<keyword>Therapeutic immunization</keyword>
	<keyword>HIV Therapeutic Vaccine</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>